NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG. Written by @lucas_marinacci!. Summary, analysis and more #ESCCongress coverage below!. @CMichaelGibson @ceciliabahit

In-Hospital Dapagliflozin Does Not Reduce CV Death or Worsening HF in Two Months, but Meta-Analysis Signals Potential Early Benefit. Written by @leahkosyakovsky!. Summary, analysis and more #ESCCongress coverage below! @CMichaelGibson @ceciliabahit

AI-Powered Virtual Assistant Boosts GDMT Optimization. ASSIST-HF SIRIO . Written by @leahkosyakovsky !. Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit

Sacubitril/Valsartan Outperforms Enalapril in HFrEF due to Chronic Chagas Cardiomyopathy (CCC): PARACHUTE-HF . Written by Dami Aladesanmi! . Summary, analysis and more #ESCCongress coverage below! @CMichaelGibson @ceciliabahit

An AI-enabled Stethoscope for Early Detection of Cardiac Conditions Increases Detection: TRICORDER. Written by Dami Aladesanmi! . Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit

Home-Based Hypertension Care Significantly Lowers Blood Pressure in Rural South Africa: The IMPACT-BP Trial. Written by Dami Aladesanmi! . Summary, analysis and more #ESCCongress coverage below! @CMichaelGibson @ceciliabahit

Zilebesiran May Benefit Selected Groups of Uncontrolled Hypertension with High CV Risk: KARDIA-3 . Written by Dami Aladesanmi!. Summary, analysis and more #ESCCongress coverage below! @CMichaelGibson @ceciliabahit

Essence-TIMI 73b: Olezarsen Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk . Written by @lucas_marinacci!. Summary, analysis and more #ESCCongress coverage below!. @CMichaelGibson @ceciliabahit

VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF. Written by @lucas_marinacci! . Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit

VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity . Written by @lucas_marinacci!. Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit

ABC-AF Trial: Personalized Risk-Based Treatment Did Not Improve Outcomes in Patients with Atrial Fibrillation. Written by @adam_dr_! . Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit

BaxHTN: Baxdrostat Significantly Reduced Blood Pressure in Patients with Uncontrolled or Resistant Hypertension. Written by @adam_dr_! . Summary, analysis and more #ESCCongress coverage below!. @CMichaelGibson @ceciliabahit

HI-PRO Trial: Extended Low-Intensity Apixaban Reduces Recurrent VTE in Patients with Provoked VTE and Enduring Risk Factors. Written by @adam_dr_! . Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit

MAPLE-HCM: Aficamten Superior to Metoprolol for Improving Exercise Capacity in Symptomatic Obstructive HCM . Written by @adam_dr_! . Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit.

An Invasive vs Conservative Strategy Safe But Does Improve MACE in Frail Older NSTEMI Patients: SENIOR-RITA Frail. Written by Dami Aladesanmi! . Summary, analysis and more #ESCCongress coverage below! . @CMichaelGibson @ceciliabahit.

LOSE-AF: Weight Loss Alone Does Not Improve AF Symptoms or Burden in Older Adults . Written by @adam_dr_! . Summary, analysis and more #ESCCongress coverage below! @CMichaelGibson @ceciliabahit.

Clopidogrel Monotherapy Significantly Reduced MACE vs Aspirin Monotherapy Post-PCI: SMART-CHOICE 3. Written by Dami Aladesanmi! . Summary, analysis and more #ACC25 coverage below! . @CMichaelGibson @ceciliabahit.

FFR-Guided PCI Associated with Higher Rates of MI Compared to CABG in MVD: Five-Year Results from FAME-3. Written by @nkong_med!. Summary, analysis and more #ACC25 coverage below!. @CMichaelGibson @ceciliabahit.

Sudden Cardiac Arrest Survival Worse in Minorities Among Young Athletes: RACER Cohort from 2010–2023. Written by @nkong_med!. Summary, analysis and more #ACC25 coverage below!. @CMichaelGibson @ceciliabahit.

Altshock2: No Benefit to IABP in HF-Cardiogenic Shock. Written by @leahkosyakovsky! . Summary, analysis and more #ACC25 coverage below! . @CMichaelGibson @ceciliabahit.